Author:
Girdauskas Evaldas,Pausch Jonas,Reichenspurner Hermann,Kempfert Jörg,Kuntze Thomas,Owais Tamer,Holubec Tomas,Krane Markus,Vitanova Keti,Borger Michael,Eden Matthias,Hachaturyan Violetta,Bramlage Peter,Falk Volkmar
Abstract
Abstract
Background
Functional mitral regurgitation (FMR) is one of the most common heart valve diseases that is a sequel of left ventricular remodelling. Although mitral valve annuloplasty is a standard treatment of FMR, the recurrence of FMR is a major drawback and occurs in 10–50% of patients. The REFORM-MR registry aims to investigate the effectiveness of standardized papillary muscle relocation and ring annuloplasty and to identify the risk factors associated with recurrent FMR.
Methods
REFORM-MR is a prospective, multicenter registry that enrols consecutive FMR patients across five sites in Germany. All patients with FMR and restricted movement of leaflets during systole (i.e., type IIIb mitral regurgitation) undergoing standardized subannular repair in combination with mitral valve annuloplasty are included in the study. The primary objective is to examine the effect of combined papillary muscle relocation and ring annuloplasty on the recurrence of FMR at 2 years postoperatively. The secondary objectives are MACCE rate, reinterventions on the mitral valve and cardiac-related mortality in the study cohort. Echocardiography core-lab and MRI core-lab will provide anonymized analysis of the imaging data in the REFORM-MR registry. Student’s t-test or Mann–Whitney U test for continuous variables and the Chi-Square or Fisher exact test for categorical variables are used for group comparisons. Kaplan–Meier analyses is performed for survival and safety outcomes.
Results
As of May 2021, a total of 97 patients were enrolled across five sites in Germany.
Conclusions
The results of this study will help define the outcomes of combined papillary muscle relocation and ring annuloplasty in the FMR treatment in a multicentre setting and to improve the understanding of the limitations of subannular repair procedures while treating patients with type III FMR.
Trial registration clinicaltrials.gov Identifier: NCT03470155.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,General Medicine,Surgery,Pulmonary and Respiratory Medicine
Reference24 articles.
1. Douedi S, Douedi H. Mitral regurgitation. Treasure Island: StatPearls Publishing; 2021.
2. Pausch J, Harmel E, Sinning C, Reichenspurner H, Girdauskas E. Standardized subannular repair for type IIIb functional mitral regurgitation in a minimally invasive mitral valve surgery setting†. Eur J Cardiothorac Surg. 2019;56(5):968–75.
3. Petrus AHJ, Dekkers OM, Tops LF, Timmer E, Klautz RJM, Braun J. Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation: long-term analysis of competing outcomes. Eur Heart J. 2019;40(27):2206–14.
4. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231–48.
5. Echarte-Morales J, Minguito-Carazo C, Benito-González T, Estévez-Loureiro R, Garrote-Coloma C, Prado APd, et al. Percutaneous treatment of mitral regurgitation recurrence after mitral valve surgery. Vessel Plus. 2021;5:54.